Bayforest Capital Ltd Has $201,000 Stock Position in Doximity, Inc. $DOCS

Key Points

• Bayforest Capital Ltd reduced its stake in Doximity, Inc. by 69.2%, owning 3,274 shares valued at $201,000 after selling 7,340 shares in the second quarter.
• Insiders of Doximity have sold a total of 37,000 shares worth $2,635,880 over the last 90 days, with notable sales by Directors Kira Scherer Wampler and Timothy S. Cabral.
• Doximity's stock has a current market cap of $12.60 billion and has a 52-week price range between $40.87 and $85.21.

Bayforest Capital Ltd decreased its position in Doximity, Inc. (NASDAQ:DOCS - Free Report) by 69.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,274 shares of the company's stock after selling 7,340 shares during the period. Bayforest Capital Ltd's holdings in Doximity were worth $201,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Ballentine Partners LLC acquired a new position in shares of Doximity in the 1st quarter valued at $201,000. Wealth Enhancement Advisory Services LLC boosted its stake in Doximity by 196.6% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 13,570 shares of the company's stock worth $787,000 after purchasing an additional 8,995 shares during the period. Bank of Nova Scotia acquired a new position in Doximity in the 1st quarter worth $651,000. New York State Teachers Retirement System boosted its stake in Doximity by 10.9% in the 1st quarter. New York State Teachers Retirement System now owns 113,145 shares of the company's stock worth $6,566,000 after purchasing an additional 11,078 shares during the period. Finally, Jump Financial LLC acquired a new position in Doximity in the 1st quarter worth $3,125,000. Institutional investors and hedge funds own 87.19% of the company's stock.

Insider Activity at Doximity

In related news, Director Kira Scherer Wampler sold 2,000 shares of the company's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $57.09, for a total value of $114,180.00. Following the transaction, the director owned 16,618 shares in the company, valued at approximately $948,721.62. This represents a 10.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Timothy S. Cabral sold 20,000 shares of the company's stock in a transaction dated Wednesday, September 24th. The shares were sold at an average price of $75.00, for a total transaction of $1,500,000.00. Following the completion of the transaction, the director owned 3,221 shares in the company, valued at approximately $241,575. This trade represents a 86.13% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 37,000 shares of company stock worth $2,635,880. Insiders own 31.30% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Bank of America upped their target price on shares of Doximity from $55.00 to $62.00 and gave the stock a "neutral" rating in a research note on Wednesday, June 25th. Wells Fargo & Company upped their target price on shares of Doximity from $55.00 to $62.00 and gave the stock an "equal weight" rating in a research note on Monday, August 4th. KeyCorp upped their target price on shares of Doximity from $75.00 to $80.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 8th. Needham & Company LLC upped their target price on shares of Doximity from $67.00 to $75.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. Finally, JPMorgan Chase & Co. reissued an "underweight" rating and set a $62.00 price target on shares of Doximity in a research report on Friday, October 10th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $69.37.

Doximity Stock Performance

Shares of DOCS stock opened at $67.27 on Friday. The firm's 50-day moving average is $69.20 and its 200-day moving average is $61.18. The stock has a market cap of $12.60 billion, a price-to-earnings ratio of 67.27, a PEG ratio of 4.10 and a beta of 1.38. Doximity, Inc. has a 52-week low of $40.87 and a 52-week high of $85.21.

Doximity (NASDAQ:DOCS - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.31 by $0.05. Doximity had a net margin of 36.60% and a return on equity of 21.75%. The business's revenue was up 15.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.28 EPS. Doximity has set its FY 2026 guidance at EPS. Q2 2026 guidance at EPS. Sell-side analysts predict that Doximity, Inc. will post 0.99 EPS for the current fiscal year.

Doximity Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.

Want to see what other hedge funds are holding DOCS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Doximity, Inc. (NASDAQ:DOCS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.